Phase II clinical study of nab-paclitaxel for patients with recurrent advanced non-small cell lung cancer.
- Conditions
- advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000016932
- Lead Sponsor
- The Japan-Multinational Trial Organization (JMTO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 81
Not provided
1) Patient with previous treatment by paclitaxel. 2) Patient receiving chemotherapies less than 4 weeks or EGFR-TKI within two weeks. 3) Patient receiving definitive radiotherapy for less than 6 weeks or local palliative radiotherapy for less than 2 weeks. 4) Patient with symptomatic brain metastasis. 5) Patient with need of chest drainage for pleural effusion. 6) Active infection. 7) Patient with severe complications. 8) Patient having autoimmune disease to need treatment by the immunosuppressive drug. 9) Patient with active multiple cancers. 10) Female Patient in or having a chance or planning of pregnancy or breast feeding. Male patient in planning to impregnate. 11) History of sever psychological disease. 12) Administering steroid. 13) Any patients judged by the investigator to be unfit to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival
- Secondary Outcome Measures
Name Time Method Overall survival/ Objective response rate/ Adverse events